IP Verse

Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy - EP3126390

The patent EP3126390 was granted to Cellectis on Oct 16, 2019. The application was originally filed on Apr 2, 2015 under application number EP15713513A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3126390

CELLECTIS
Application Number
EP15713513A
Filing Date
Apr 2, 2015
Status
Granted And Under Opposition
Sep 13, 2019
Grant Date
Oct 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJul 14, 2020ADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2004058414
INTERNATIONAL-SEARCH-REPORTUS2013309223
INTERNATIONAL-SEARCH-REPORTWO2004043344
INTERNATIONAL-SEARCH-REPORTWO2011036183
INTERNATIONAL-SEARCH-REPORTWO2012079000
OPPOSITIONUS2012251554
OPPOSITIONWO2004043344
OPPOSITIONWO2013123061
OPPOSITIONWO2013173496
OPPOSITIONWO2013176915

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "CD3 (immunology)", Wikipedia, (20200603), pages 1 - 3, Wikipedia, (20210119), XP055766647-
OPPOSITION- Anonymous, "Illawarra", Collins English Dictionary, (19920101), page 774, XP055766577-
OPPOSITION- Anonymous, "METHOTREXATE", Wikipedia, (20200511), pages 1 - 9, XP055766587-
OPPOSITION- Carol E. O'Hear, Joshua Heiber, Terrence L. Geiger, "Anti-CD33 Chimeric Antigen Receptor Therapy For Acute Myeloid Leukemia", Blood, American Society of Hematology, US, US, vol. 122, no. 21, ISSN 0006-4971, (20131101), page 1441, Blood, URL: https://ash.confex.com/ash/2013/webprogram/Paper65623.html, (20140822), XP002727865-
OPPOSITION- Poirot Laurent et al, "T-Cell Engineering For "off-The-shelf" Adoptive Immunotherapy", Blood, American Society of Hematology, US, US, (20131115), vol. 122, no. 21, ISSN 0006-4971, page 1661, XP009187449-
OPPOSITION- Poirot Laurent Poirot et al, "T-Cell Engineering for Adoptive Immunotherapy Using TAL-Effector Nucleases (TALENTM)", Molecular Therapy, No longer published by Elsevier, (20130601), vol. 21, no. Suppl.1, ISSN 1525-0016, page S154, XP009177171-
OPPOSITION- SADELAIN MICHEL, BRENTJES R, RIVIERE I, "The promise and potential pitfalls of chimeric antigen receptors", CURRENT OPINION IN IMMUNOLOGY., ELSEVIER, OXFORD., GB, GB, (20090101), vol. 21, no. 2, doi:10.1016/J.COI.2009.02.009, ISSN 0952-7915, pages 215 - 223, XP002667114
OPPOSITION- Michael C. Milone et al, "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", Molecular Therapy, No longer published by Elsevier, (20090801), vol. 17, no. 8, doi:10.1038/MT.2009.83, ISSN 1525-0016, pages 1453 - 1464, XP002732433
OPPOSITION- IMAI C, ET AL, "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.", Blood Cancer Journal (Leukemia), Nature Publishing Group UK, London, London, (20040401), vol. 18, no. 4, ISSN 0887-6924, pages 676 - 684, XP002579934
OPPOSITION- E Mejstříková, T Kalina, J Trka, J Starý, O Hrušák, "Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20050601), vol. 19, no. 6, doi:10.1038/sj.leu.2403737, ISSN 0887-6924, pages 1092 - 1094, XP055766621
OPPOSITION- N Robillard, S Wuillème, L Lodé, F Magrangeas, S Minvielle, H Avet-Loiseau, "CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20051101), vol. 19, no. 11, doi:10.1038/sj.leu.2403948, ISSN 0887-6924, pages 2021 - 2022, XP055766627
OPPOSITION- M De Lima, Et Al, "Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20080201), vol. 22, no. 2, doi:10.1038/sj.leu.2405014, ISSN 0887-6924, pages 258 - 264, XP055766624
OPPOSITION- Cory D. Rillahan et al, "Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas", CHEMICAL SCIENCE, Royal Society of Chemistry, United Kingdom, United Kingdom, (20140101), vol. 5, no. 6, doi:10.1039/c4sc00451e, ISSN 2041-6520, page 2398, XP055405201
OPPOSITION- Campana Dario; Schwarz Herbert; Imai Chihaya, "4-1BB chimeric antigen receptors.", Cancer Journal, USA, USA, (20140301), vol. 20, no. 2, doi:10.1097/PPO.0000000000000028, ISSN 1540-336X, pages 134 - 140, XP009181091
OPPOSITION- SCHWEMMLEIN MICHAEL et al, "A CD33-SPECIFIC SINGLE-CHAIN IMMUNOTOXIN MEDIATES POTENT APOPTOSIS OF CULTURED HUMAN MYELOID LEUKAEMIA CELLS", British Journal of Haematology, Wiley-Blackwell Publishing Ltd., GB, GB, (20060401), vol. 133, no. 2, doi:10.1111/j.1365-2141.2005.05869.x, ISSN 0007-1048, pages 141 - 151, XP009080463
OPPOSITION- Naohi Sahara, Et Al, "Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma", European journal of haematology, MUNSKGAARD, COPENHAGEN., DK, DK, (20060701), vol. 77, no. 1, doi:10.1111/j.1600-0609.2006.00661.x, ISSN 0902-4441, pages 14 - 18, XP055766630
OPPOSITION- A. Dutour et al, "In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia", Advances in Hematology, Hindawi Publishing Corporation, (20120101), vol. 2012, doi:10.1155/2012/683065, ISSN 1687-9104, pages 683065 - 683065-10, XP055153685
OPPOSITION- M. V. Maus, S. A. Grupp, D. L. Porter, C. H. June, "Antibody-modified T cells: CARs take the front seat for hematologic malignancies", Blood, (20140424), vol. 123, no. 17, doi:10.1182/blood-2013-11-492231, ISSN 00064971, pages 2625 - 2635, XP055185132
OPPOSITION- Mannioui C, "Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB, (20131107), vol. 1, no. Suppl 1, doi:10.1186/2051-1426-1-S1-P34, ISSN 2051-1426, page P34, XP021167243
OPPOSITION- Roman Galetto et al, "Pre-T cell receptor for improved expansion of TCR alpha disrupted T cells", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB, (20131107), vol. 1, no. Suppl 1, doi:10.1186/2051-1426-1-S1-P9, ISSN 2051-1426, page P9, XP021167303
OPPOSITION- V. Marin et al, "Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors", Haematologica, (20101201), vol. 95, no. 12, doi:10.3324/haematol.2010.026310, ISSN 03906078, pages 2144 - 2152, XP055153706
OPPOSITION- H. Herrmann, Et Al, "CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin", Haematologica, Fondazione Ferrata Storti, IT, IT, (20120201), vol. 97, no. 2, doi:10.3324/haematol.2010.035006, ISSN 0390-6078, pages 219 - 226, XP055766614
OPPOSITION- C. O'hear, J. F. Heiber, I. Schubert, G. Fey, T. L. Geiger, "Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia", Haematologica, Fondazione Ferrata Storti, IT, IT, (20150301), vol. 100, no. 3, doi:10.3324/haematol.2014.112748, ISSN 0390-6078, pages 336 - 344, XP055227759

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents